Table 1.
Baseline Demographic and Clinical Characteristics of the Participants as a Group and Split Based on SSRI Use at Study Entry [Mean±SD, unless noted otherwise]
| Variable | Total Sample N=264 |
No-SSRI Group N=137 |
SSRI Group N=127 |
p-value |
|---|---|---|---|---|
|
| ||||
| Age, years | 18.9±1.6 | 19.0±1.5 | 18.8±1.7 | >0.40 |
|
| ||||
| Female Sex, n (%) | 159 (60) | 76 (55) | 83 (65) | >0.10 |
|
| ||||
| Time since Menarche, years | 6.3±2.3 | 6.5±2.3 | 6.1±2.2 | >0.20 |
|
| ||||
| White Race, n (%) | 233 (88) | 119 (87) | 114 (90) | >0.30 |
|
| ||||
| Hispanic, n (%) | 22 (8) | 11 (8) | 11 (9) | >0.80 |
|
| ||||
| BMI Z-score | 0.43±0.93 | 0.40±1.00 | 0.46±0.90 | >0.50 |
|
| ||||
| LBMI Z-score | −0.52±0.93 | −0.53±0.94 | −0.52±0.91 | >0.90 |
|
| ||||
| Physical Activity Score* | 2.0±0.7 | 2.0±0.7 | 2.0±0.8 | >0.30 |
|
| ||||
| Estimated Daily Caloric Intake, kcal | 1762±941 | 1715±816 | 1814±1064 | >0.40 |
|
| ||||
| Cigarette Use, n (%) | 41 (16) | 16 (12) | 25 (20) | <0.08 |
|
| ||||
| Alcohol Use, n (%) | 183 (69) | 95 (69) | 88 (69) | >0.90 |
|
| ||||
| Psychiatric Characteristics | ||||
|
| ||||
| MDD at Study Entry, n (%) | <0.0001 | |||
| - Symptomatic | 131 (50) | 29 (21) | 102 (80) | |
| - In Full Remission | 42 (16) | 27 (20) | 15 (12) | |
| - Never | 91 (34) | 81 (59) | 10 (8) | |
| MDD at Study End, n (%) | <0.0001 | |||
| - Symptomatic | 74 (28) | 20 (15) | 54 (43) | |
| - In Full Remission | 113 (43) | 47 (34) | 66 (52) | |
| - Never | 77 (29) | 70 (51) | 7 (6) | |
|
| ||||
| Percent Time Meeting Full MDE Criteria¶ | 23.9±29.9 | 11.2±23.5 | 37.6±29.9 | <0.0001 |
|
| ||||
| IDS Score | 13.9±10.8 | 7.9±8.1 | 20.3±9.5 | <0.0001 |
|
| ||||
| BDI Score | 11.1±10.5 | 5.7±6.5 | 16.9±10.8 | <0.0001 |
|
| ||||
| GAD at Study Entry, n (%) | 73 (28) | 23 (17) | 50 (39) | <0.0001 |
|
| ||||
| Percent Time Meeting GAD Criteria¶ | 39.5±37.7 | 25.0±33.5 | 55.1±35.9 | <0.0001 |
|
| ||||
| BAI Score | 8.3±8.6 | 4.4±5.0 | 12.6±9.6 | <0.0001 |
|
| ||||
| SSRI Use at Study End, n (%) | 65 (25) | 2 (1) | 63 (50) | <0.0001 |
|
| ||||
| Duration of SSRI Use, years | 0.44±0.67 | 0.02±0.18 | 0.90±0.70 | <0.0001 |
MDD/MDE: major depressive disorder/episode, IDS: inventory of depressive symptomatology, BDI/BAI: Beck depression and Beck anxiety inventory, BMI: Body Mass Index, BMI Z-score: age-sex-specific BMI Z-score, FMI Z-score: age-sex-specific fat mass index Z-score, GAD: generalized anxiety disorder, LBMI Z-score: age-sex-specific lean body mass index Z-score, SSRI: selective serotonin reuptake inhibitor.
Physical Activity Score 1=low, 5=high.
Percent time meeting full MDE or GAD criteria capture the percentage of weeks where the participant met DSM-IV-TR criteria for a major depressive episode or generalized anxiety disorder, based on the Longitudinal Interview Follow-up Evaluation for Adolescents (A-LIFE).
Bolded results are statistically significant (p<0.05) and italicized and bolded results are marginally significant (p<0.10).